Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular ...
Cardio Diagnostics Holdings, Inc. (CDIO) is a Chicago-based biotechnology company focused on advancing cardiovascular disease prevention and early diagnosis through epigenetic insights and AI-enabled analytics. The company develops clinical diagnostic tools that translate biological signals—particularly epigenetic patterns—into practical risk information intended to support earlier and more personalized decision-making in heart ...Cardio Diagnostics Holdings, Inc. (CDIO) is a Chicago-based biotechnology company focused on advancing cardiovascular disease prevention and early diagnosis through epigenetic insights and AI-enabled analytics. The company develops clinical diagnostic tools that translate biological signals—particularly epigenetic patterns—into practical risk information intended to support earlier and more personalized decision-making in heart health.
A central product offering highlighted in the company description is Epi+Gen CHD, a diagnostic test designed to estimate an individual’s three-year risk of developing symptomatic coronary heart disease. The company’s broader platform approach emphasizes using an integrated genetic-epigenetic engine (often described as AI-driven) to help connect molecular measurements to clinically meaningful outcomes. In this model, the value proposition is to move beyond traditional risk scores by incorporating multi-omic information to potentially improve risk stratification and identify higher-risk individuals sooner.
From a business and go-to-market perspective, CDIO is oriented around commercialization of laboratory and clinical testing services/products, which typically involve: test development and validation, clinical workflow integration, regulatory and quality processes, and the ability to generate consistent results that are interpretable for clinicians and patients. The company’s work is also data-driven—there is an implied emphasis on data intelligence and ongoing learning from test-related information to refine predictive outputs.
Cost and economics for a diagnostics company commonly depend on R&D and clinical validation spend, laboratory processing costs, and commercialization expenses such as sales/marketing and reimbursement support. The supplied financial snapshot (TTM) indicates negative profitability metrics (e.g., gross profit margin and net/operating profit margins are negative) and negative cash flow measures (free cash flow and operating cash flow ratios are negative), which is consistent with an early or investment-heavy commercialization stage typical for emerging diagnostics. The company also reports relatively strong liquidity ratios such as a high current ratio (TTM) and cash/quick ratios in the provided dataset, suggesting the company has some short-term financial runway even while profitability is not yet positive.
Key people include CEO and co-founder Dr. Meesha (Meeshanthini) V. Dogan, PhD, and co-founder and Chief Medical Officer Dr. Rob Philibert, MD, PhD. Their leadership background reflects both scientific/technical and clinical perspectives, which is important for diagnostics companies that must bridge assay performance with clinical utility.
Looking ahead, the “wish list” for a company like CDIO typically centers on: expanding adoption of its tests by clinicians and healthcare systems, demonstrating clinical utility and improving payer/reimbursement pathways, scaling laboratory throughput to reduce per-test cost, and building evidence (clinical studies and real-world outcomes) to strengthen differentiation. As CDIO continues to execute on its epigenetics-based approach, success would likely be measured by increased test utilization, improved unit economics, and progression toward sustainable profitability.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$14825
-57.5%
+100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-6.5M
+22.5%
+16.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
0.0%
+102.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-43737.5%
-82.4%
+58.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-43832.5%
-82.4%
+58.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.9M
-9.6%
+14.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-39893.1%
-157.9%
+57.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
10.0%
-1.7%
-16.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
9.79x
-29.7%
+8.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
